The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

24 March 2022

Osirium Technologies plc

("Osirium" or the "Group")

Contract win for Privileged Process Automation solution with a leading provider of services to the UK Healthcare sector

Osirium's largest PPA deal to date

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cybersecurity and IT automation software, is pleased to announce a contract win at Midlands and Lancashire Commissioning Support Unit (MLCSU) for its Privileged Process Automation (PPA) and Privileged Access Management (PAM) solutions. MLCSU supports 50 Clinical Commissioning Groups (CCGs), NHS GP federations, and local authorities in the north of England.

This is the Group's first customer win where the PPA order is significantly larger than the PAM element. 

PPA is Osirium's solution for automating IT and business processes that traditionally require expert skills and auditability. It is one of the three core products in the Group's Privileged Access Security suite, alongside Privileged Access Management and Privileged Endpoint Management. This contract with MLCSU reflects Osirium's increasing success in marketing its PPA and PEM solutions as primary or standalone products.

PPA will be rolled out initially to 600 users and 100 IT servers and systems in GP surgeries at one of MLCSU's CCG clients, with the potential for a further roll out in due course. By deploying PPA at GP surgeries, staff can action updates such as resetting user accounts immediately, without needing to know complex IT management systems, the privileged access credentials for user accounts, or submitting requests to a central IT help desk and waiting for a response. The result will be less disruption to users, and reduced workloads for the IT administrators.

Key to selecting PPA was ease of use at the GP surgeries. User testing showed that PPA's unique conversational style of interaction with users meant that complex operations could be used with little or no training.

Osirium worked closely with its specialist healthcare partner, ITHealth, to ensure the Osirium solution could address the needs of MLCSU.

David Guyatt, Chief Executive Officer, commented: "Secure automation is the way that any organisation, especially the over-stretched NHS, can deliver more benefits to patients and staff while improving security. We see Automation as a significant area of growth and there is a growing interest in PPA as a primary or standalone solution.

Importantly, the model being adopted by MLCSU's clients is applicable across a wide range of industries such as retail, hospitality, and transportation, providing the opportunity for wide-scale deployment to new and existing customers. We expect this product to become an important contributor to Osirium's revenue in line with this broader market awareness."

For further information:

Notes to Editors:

Osirium Technologies plc (AIM: OSI) is a leading UK-based cybersecurity software vendor delivering Privileged Access Management (PAM), Privileged Endpoint Management (PEM) and Osirium Automation solutions that are uniquely simple to deploy and maintain. 

With privileged credentials involved in over 80% of security breaches, customers rely on Osirium PAM's innovative technology to secure their critical infrastructure by controlling 3^rd party access, protecting against insider threats, and demonstrating rigorous compliance. Osirium Automation delivers time and cost savings by automating complex, multi-system processes securely, allowing them to be delegated to Help Desk engineers or end-users and to free up specialist IT resources. The Osirium PEM solution balances security and productivity by removing risky local administrator rights from users, while at the same time allowing escalated privileges for specific applications.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to trading on AIM in April 2016. For further information please visit www.osirium.com.